Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Alfonso Eduardo acquired 4,300 common shares on March 2, 2026, at around $17.90 per share, for a total transaction value of ~$77,000. Bausch + Lomb, matched his purchase with restricted stock units, raising his direct holdings to 13,855 shares post-transaction.

Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced positive 24-month results from the pivotal U.S. clinical trial of the ELIOS System. Developed for the treatment of elevated intraocular pressure (IOP) in patients with open angle glaucoma, ELIOS is an implant-free procedure that uses next generation excimer laser technology. The ELIOS procedure is currently CE m.

LOS ANGELES, March 13, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Bausch + Lomb Corporation, (“BLCO" or the "Company") (NYSE:BLCO) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Caspian Capital increased its Bausch + Lomb Corporation stake by 1,349,043 shares in the fourth quarter; the estimated trade value was $21.39 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $21.61 million, reflecting both trading and price changes.

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D “Teach-in” webinar series that will provide deeper insights on the company's differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hasha.

Bausch + Lomb (BLCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).